Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fluzoparil plus paclitaxel neoadjuvant study in germline BRCA-mutated triple-negative breast cancer
ChiCTR2200060739Phase 4Not yet recruiting
- Sponsor
- Jiangsu Provincial People's Hospital
- Start
- Apr 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of fluzoparib and paclitaxel in triple-negative breast cancer (TNBC) (2 arms), sponsored by Jiangsu Provincial People's Hospital. Primary endpoint: Pathologic complete response rate. Planned start Apr 2022; status: not yet recruiting.
02
Drugs
fluzoparibpaclitaxel
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on ChiCTR2200060739.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200060739.